1.
Kennedy PG. Varicella-zoster virus latency in human ganglia.Rev Med Virol. 2002;12(5):327-334.
2.
Nagel MA, Gilden DH. The protean neurologic manifestationsof varicella-zoster virus infection. Cleveland Clin J Med. 2007;74(7):489.
3.
Gilden D, Cohrs RJ, Mahalingam R, Nagel MA. Neurologicaldisease produced by varicella zoster virus reactivation without rash.Varicella-zoster Virus. 2010:243-253. doi.org/10.1007/82_2009_3
4.
Gershon AA, Gershon MD. Pathogenesis and current approachesto control of varicella-zoster virus infections. Clin Microbiol Rev.2013;26(4):728-743.
5.
Furuta Y, Ohtani F, Aizawa H, Fukuda S, Kawabata H, BergströmT. Varicella-zoster virus reactivation is an important cause ofacute peripheral facial paralysis in children. Pediatr Infect Dis J.2005;24(2):97-101.
6.
Breuer J, Pacou M, Gautier A, Brown MM. Herpes zoster as a riskfactor for stroke and TIA: a retrospective cohort study in the UK.Neurol. 2014;83(2):e27-e33.
7.
Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinicalmanifestations and management. Viruses. 2022;14(2):192.
8.
Zhou J, Li J, Ma L, Cao S. Zoster sine herpete: a review. Korean JPain. 2020;33(3):208-215.
9.
Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ.Antiviral therapy for herpes zoster: randomized, controlledclinical trial of valacyclovir and famciclovir therapy inimmunocompetent patients 50 years and older. Arch Fam Med.2000;9(9):863.
10.
McDonald EM, de Kock J, Ram FS. Antivirals for managementof herpes zoster including ophthalmicus: a systematic reviewof high-quality randomized controlled trials. Antiviral Ther.2012;17(2):255-264.
11.
Lin W, Lin H, Lee S, et al. Comparative study of the efficacy andsafety of valaciclovir versus acyclovir in the treatment of herpeszoster. J Microbiol Immunol Infect= Wei Mian yu gan ran za zhi.2001;34(2):138-142.
12.
Gershon AA, Breuer J, Cohen JI, et al. Varicella zoster virusinfection. Nature Rev Dis Primers. 2015;1(1):1-18.
13.
Whitley RJ, Weiss H, Gnann Jr JW, et al. Acyclovir withand without prednisone for the treatment of herpes zoster:a randomized, placebo-controlled trial. Ann Internal Med.1996;125(5):376-383.
14.
Han Y, Zhang J, Chen N, He L, Zhou M, Zhu C. Corticosteroidsfor preventing postherpetic neuralgia. Cochrane DatabaseSystematic Rev. 2013;3:1-33.
15.
Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, LanganSM. Quantification of risk factors for herpes zoster: populationbased case-control study. BMJ. 2014;348:g2911. doi.org/10.1136/bmj.g2911
16.
Chen JJ, Zhu Z, Gershon AA, Gershon MD. Mannose6-phosphate receptor dependence of varicella zoster virusinfection in vitro and in the epidermis during varicella and zoster.Cell. 2004;119(7):915-926.
17.
Yang Y, Mahmood T, Siddiqui AH, Aziz MA. Zoster sine herpete:two unusual cases of varicella-zoster reactivation with atypicalcomplaints of acute chest pain and severe headache. BMC InfectDis. 2023;23(1):239. doi:10.1186/s12879-023-08093-3
18.
Drago F, Herzum A, Ciccarese G, Broccolo F, Rebora A, Parodi A.Acute pain and postherpetic neuralgia related to Varicella zostervirus reactivation: comparison between typical herpes zoster andzoster sine herpete. J Med Virol. 2019;91(2):287-295.
19.
Chen WH, Chui C, Yin HL. Zoster sine herpete, vertebralartery stenosis, and ischemic stroke. J Stroke Cerebrovasc Dis.2013;22(7):e234-e237.
20.
Ibraheem M, Marin M, Leung J, et al. Fatal wild-type varicella-zoster virus encephalitis without a rash in a vaccinated child.Pediatr Infect Dis J. 2013;32(2):183-185.